Skip to main content
OpenTrials
Completed

NCT Number: NCT03929783

Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings

This pilot trial studies how well contrast enhanced mammography works in diagnosing patients with suspicious breast findings. Diagnostic procedures, such as contrast enhanced mammography, may help to reclassify findings seen on diagnostic mammography and ultrasound as benign or likely benign with what would otherwise require biopsy for confirmation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

About this study

PRIMARY OBJECTIVES:

I. To obtain preliminary data to support the hypothesis that contrast enhanced mammography (CEM) can reduce benign tissue diagnosis (FP3) and therefore improve positive predictive value 3 (PPV3).

SECONDARY OBJECTIVES:

I. Identify specific CEM characteristics that accurately classify a finding as benign, high-risk or malignant.

II. Assess the positive and negative predictive values for each digital breast tomosynthesis (DBT), breast ultrasound and CEM.

EXPLORATORY OBJECTIVES:

I. To compare the outcomes/endpoints stratified by age to determine if age affects the ability of CEM to accurately define a lesion as benign, probably benign or suspicious.

OUTLINE:

Patients undergo contrast enhanced mammography prior to scheduled standard of care core needle biopsy of the breast on the same day or up to 3 days later.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with digital breast tomosynthesis and/or ultrasound assessments of Breast Imaging Reporting and Data System (BI-RADS) 4 and 5 lesions with recommendation of needle biopsy for tissue diagnosis.
  • Abnormal findings include masses, focal, global or developing asymmetries, architecture distortions, or > 1 cm of suspicious calcifications with or without associated ultrasound abnormal findings.
  • Scheduled for imaging guided percutaneous needle biopsy.
  • Provide signed and dated informed consent form.
  • If patient is of childbearing potential, a negative pregnancy test, urine or blood, within 14 days prior to the scan.

Exclusion criteria

  • < 1 cm span of calcifications without an ultrasound correlate.
  • Pregnant patients.
  • Patients with known allergy to iodinated contrast material.
  • If patient answers YES to any of the below questions they need glomerular filtration rate (gFR) prior to contrast administration regardless of their age:
  • Have you ever been told you have renal problems?
  • Have you ever been told you have protein in your urine?
  • Do you have high blood pressure?
  • Do you have diabetes?
  • Do you have gout?
  • Have you ever had kidney surgery?

Treatment and study plan

Contrast Enhanced Digital Mammography

Procedure

Undergo CEM

Other names: CEDM, Contrast Enhanced Spectral Mammography

Primary outcomes

  1. Sensitivity of contrast enhanced mammography (CEM) to classify a lesion as benign, probably benign, or suspicious

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (mammogram+ultrasound [MM+US] and CEM) will be calculated and compared to a final tissue diagnosis independently.

  2. Sensitivity of MM to classify a lesion as benign, probably benign, or suspicious

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  3. Sensitivity of US to classify a lesion as benign, probably benign, or suspicious

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  4. Specificity of CEM to classify a lesion as benign, probably benign, or suspicious

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  5. Specificity of MM to classify a lesion as benign, probably benign, or suspicious

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  6. Specificity of US to classify a lesion as benign, probably benign, or suspicious

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  7. False negative rate of CEM

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  8. False negative rate of MM

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  9. False negative rate of US

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  10. False positive rate of CEM

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  11. False positive rate of MM

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

  12. False positive rate of US

    Time frame: Up to 1 year

    The total number of suspicious and benign lesions on each modality (MM+US and CEM) will be calculated and compared to a final tissue diagnosis independently.

Secondary outcomes

  1. Positive predictive value of CEM

    Time frame: Up to 1 year

    The positive predictive value of CEM will be calculated and compared to MM+US.

  2. Positive predictive value of MM

    Time frame: Up to 1 year

    The positive predictive value of CEM will be calculated and compared to MM+US.

  3. Positive predictive value of US

    Time frame: Up to 1 year

    The positive predictive value of CEM will be calculated and compared to MM+US.

  4. Negative predictive value of CEM

    Time frame: Up to 1 year

    The negative predictive value of CEM will be calculated and compared to MM+US.

  5. Negative predictive value of MM

    Time frame: Up to 1 year

    The negative predictive value of CEM will be calculated and compared to MM+US.

  6. Negative predictive value of US

    Time frame: Up to 1 year

    The negative predictive value of CEM will be calculated and compared to MM+US.

Sponsors and collaborators

Lead sponsor

Thomas Jefferson University

Other

Registry information

Official study title

Improving PPV3 Using Contrast Enhanced Mammography (CEM) in Diagnostic Assessment by Reducing Benign Tissue Diagnosis (FP3) - A Single-Arm Prospective Study

Important dates

Study start
2020
Primary completion
2021
Study completion
2023
First posted
Apr 29, 2019
Registry last updated
Apr 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.